ALKERMES | ALKS - Umlaufvermögen

Aktienkurs
27.73
Täglich Wechseln
0.09 0.33%
Monatlich
-15.71%
Jährlich
-18.51%
Q1 Prognose
27.77




Umlaufvermögen Veränderung Datum
AbbVie USD 29.06B 523M 2025-12
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
ALKERMES USD 1.93B 187.5M 2025-12
Amgen USD 29.06B 1.17B 2025-12
Biogen USD 8.97B 37.5M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Coherus Biosciences USD 206.71M 254.25M 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
Heron Therapeutics USD 229.4M 18.48M 2025-09
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
J&J USD 55.62B 1.01B 2025-12
Malin Corporation EUR 62.6M 26.7M 2024-12
Merck USD 47.56B 10.49B 2025-09
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 281.36M 94.79M 2025-09
Neurocrine Biosciences USD 2.52B 364.3M 2025-12
Otsuka Holdings JPY 1.62T 113.12B 2025-12
Ovoca Bio EUR 4.96M 2.06M 2022-06
Pfizer USD 46.92B 3.22B 2025-09
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12